Therapy of ocular behçet disease

Ocular Immunology and Inflammation

Volumn 22, Issue 1, 2014, Pages 64-76

  Zierhut, Manfred ^a   Abu El Asrar, Ahmet M ^b   Bodaghi, Bahram ^c   Tugal Tutkun, Ilknur ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Behcet's disease; Biologicals; Immunosuppression; Therapy; Uveitis

Indexed keywords

BEHCET SYNDROME; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84893432656     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.866257     Document Type: Review

References (152)

1. Saka T, Takeno M. New approaches to Behçet's disease. Exp Opin Invest Drugs. 2000;9:1993-2005.
2. Takeuchi, M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefe's Arch Clin Exp Ophthalmol. 2005;243(11):1147-1152.
3. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease: An analysis of 880 patients. Am J Ophthalmol. 2004;138:373-380.
4. Kitaichi N, Miyazaki A, Iwata D, et al. Ocular features of Behçet's disease: An international collaborative study. Br J Ophthalmol. 2007;91:1578-1582.
5. Tugal-Tutkun I, CingüK, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1169-1177.
6. Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behçet disease. Ocul Immunol Inflamm. 2009;17:41-46.
7. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662.
8. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990;322: 281-285.
9. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: A single masked trial. Br J Ophthalmol. 1992;76:241-243.
10. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc. 1988;20:136-143.
11. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-Term open study of cyclosporin in Behçet's disease. Lancet. 1989;1: 1093-1096.
12. Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon a combined with azathioprine for the uveitis of Behçet's disease: An open study. Isr Med Assoc J. 2002;4:928-930.
13. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-431.
14. Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: A comparative 4-week study. Rheumatology (Oxford). 2011;50:593-597.
15. Toker E, Kazokoǧlu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol. 2002;86:521-523.
16. Yalçindag FN, Can E, Ozdemir O. Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease. Ann Ophthalmol (Skokie). 2007;39:194-197.
17. Karacorlu M, Mudun B, Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol. 2004;138:289-291.
18. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23:395-401.
19. Deuter CM, Kötter I, Wallace GR, et al. Behçet's disease: Ocular effects and treatment. Prog Retin Eye Res. 2008;27: 111-136.
20. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001;44: 2686-2692.
21. Masuda K, Urayama A, Kogure M, et al. Double-masked trial of cyclosporin versus colchicine and long-Term open study of cyclosporin in Behçet's disease. Lancet. 1989;1: 1093-1096.
22. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: Effects on long-Term prognosis. Arthritis Rheum. 1997;40:769-774.
23. Taylor SR, Singh J, Menezo V, et al. Behçet disease: Visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152:1059-1066.
24. Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res (Hoboken). 2010;62:1733-1738.
25. Akman-Demir G, Ayranci O, Kurtuncu M, et al. Cyclosporine for Behçet's uveitis: Is it associated with an increased risk of neurological involvement?. Clin Exp Rheumatol. 2008;26:S84-S90.
26. Tanabe K. Calcineurin inhibitors in renal transplantation: What is the best option?. Drugs. 2003;63:1535-1548.
27. Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease: Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc. 1991;23:3343-3346.
28. Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008; 146:752-760.
29. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416-1421.
30. Shugaiv E, Tüzün E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: Presentation of four cases. Clin Exp Rheumatol. 2011;29:S64-S67.
31. Tessler HH, Jennings T. High-dose short-Term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol. 1990;74:353-357.
32. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-Term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm. 2001;9:219-229.
33. El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139:177-184.
34. El-Asrar AM, Al-Obeidan SS, Kangave D, et al. CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Immunobiology. 2011;216:1004-1009.
35. Mage JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease: A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544-1549.
36. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behçet's disease treated with infliximab. Cytokine. 2003;24:210-218.
37. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: Soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128-132.
38. Evereklioglu C, Er H, Turkoz Y, et al. Serum levels of TNFa, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002;11:87-93.
39. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-Alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm. 2004;12:53-58.
40. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factoralpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
41. Greiner K, Murphy CC, Willermain F, et al. Anti-TNF a therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170-176.
42. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent sight-Threatening ocular inflammation in Adamantiades-Behçet's disease. Ann Intern Med. 2004;140: 404-406.
43. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum. 2005;52:2478-2484.
44. Ohno S, Makamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
45. Lantbier N, Parc C, Scavennec R, et al. Infliximab in the treatment of posterior uveitis in Behçet's disease: Long term follow-up in four patients. Press Med. 2005;34:916-918.
46. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22:S14-S16.
47. Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-Term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26: 83-92.
48. Niccoli L, Nannini C, Benucci M, et al. Long-Term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: A 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161-1164.
49. Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behçet's uveitis: An open-label trial. Rheumatol Int. 2008;29:53-57.
50. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol. 2007;51:191-196.
51. Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245-1250.
52. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol. 2008;146: 845-850.
53. Tognon S, Graziani G, Marcolongo R. Anti-TNF-A therapy in seven patients with Behçet's disease: Advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110: 474-484.
54. Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease. Ocul Immunol Inflamm. 2012;20:193-197.
55. Capella MJ, Foster CS. Long-Term efficacy and safety of infliximab in the treatment of Behçet's disease. Ocul Immunol Inflamm. 2012;20:198-202.
56. Okada AA, Goto H, Ohno S, Mochizuki M. Ocular Behçet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet's disease. Arch Ophthalmol. 2012;130:592-598.
57. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-Threatening panuveitis in Behçet's disease. Lancet. 2001;358:295-296.
58. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cycstoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648-650.
59. Noda E, Yamanishi S, Shiraishi A, Ohashi Y. Cataract surgery under infliximab therapy in a patient with Behçet's disease. J Ocul Pharmacol Ther. 2009;25:467-470.
60. Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behçet disease. Jpn J Ophthalmol. 2010;54:360-361.
61. Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet's disease. Case Report Ophthalmol. 2011;2:189-192.
62. Elezoglou A, Kafasi N, Kaklamanis PH, et al. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol. 2007;25:S65-S69.
63. Iwata D, Namba K, Mizuuchi K, et al. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol. 2012;250:1081-1087.
64. Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Behçet's disease with infliximab: A case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis. 2007;66:136-137.
65. Sarwar H, McGrath Jr. H, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol. 2005;32:181-183.
66. Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Int Ophthalmol. 2010; 30:577-581.
67. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to metrotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, pacebo-controlled trial. Arthritis Rheum. 2005;51:27-35.
68. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56:2129-2134.
69. Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-Term follow-up. World J Gastroenterol. 2007;13:5238-5244.
70. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: Experience in 19 patients. Rheumatology (Oxford). 2012;51:1825-1831.
71. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet's disease. Ocul Immunol Inflamm. 2010;18:226-232.
72. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-Threatening uveitis in Behçet's disease. Eye (Lond). 2007;21:824-825.
73. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-Allergic patient with severe Behçet's disease-related uveitis. Rheumatol Int. 2011;31:243-245.
74. Olivieri I, Leccese P, D'Angelo S, et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54-S57.
75. Mesquida M, Victoria Hernández M, Llorenç V, et al. Behçet disease-Associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21:160-162.
76. Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007;13: 543-551.
77. Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN teatment. J Immunol. 1993;150: 4687-4692.
78. Treusch M, Vonthein R, Baur M, et al. Influence of human recombinant interferon-Alpha2a (rhIFN-A 2a) on altered lymphocyte subpopulations and monocytes in Behçet's disease. Rheumatology (Oxford). 2004;43: 1275-1282.
79. Kötter I, Deuter C, Stübiger N, Zierhut M. Interferon-A (IFN-A) application versus tumor necrosis factor-A antagonism for ocular Behçet's disease: Focusing more on IFN. J Rheumatol. 2005;32:1633; author reply 1634.
80. Yang DS, Galatowicz G, Calder VL. Upregulation of Foxp3 expression by recombinant interferon-Alpha therapy in Behçet's disease. Poster No 1535 ARVO 2009.
81. Hurst EA, Mauro T. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: A case report and review of the literature. Arch Dermatol. 2005;141:865-868.
82. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: A basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13:335-351.
83. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon a in Behçet disease: Review of the literature. Semin Arthritis Rheum. 2004;33:320-355.
84. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-431.
85. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-Alfa therapy in patients with Behçet uveitis. Graefe's Arch Clin Exp Ophthalmol. 2006;244: 1692-1695.
86. Stübiger N, Kötter I, Zierhut M. Complete regression of retinal neovascularisation after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol. 2000;84: 1437-1438.
87. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol. 2006;50:256-265.
88. Gueudry J, Wechsler B, Terrada C, et al. Long-Term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146:837-844.
89. Krause L, Altenburg A, Pleyer U, et al. Long-Term visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-A-2a. J Rheumatol. 2008;35: 896-903.
90. Deuter CME, Zierhut M, Möhle A, et al. Long-Term remission after cessation of interferon-A treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010;62:2796-2805.
91. Deuter CME, Kötter I, Wallace GR, et al. Behçet's disease: Ocular effects and treatment. Prog Ret Eye Res 2008;27: 111-136.
92. Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662.
93. Deuter CM, Kötter I, Günaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906-913.
94. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrosprective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335-339.
95. Plskova J, Greiner K, Forrester JV. Interferon-A as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55-61.
96. Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving interferon-Alpha therapy. Cancer. 1990;65:2237-2242.
97. Doycheva D, Deuter CME, Stübiger N, et al. Interferonalpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247:675-680.
98. Onal S, Savar F, Akman M, Kazokoglu H. Vision-And health-related quality of life in patients with Behçet uveitis. Arch Ophthalmol. 2010;128:1265-1271.
99. Sakai T, Watanabe H, Kuroyanagi K, et al. Health-And vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis. Br J Ophthalmol. 2013;97: 338-342.
100. Gül A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy. 2005;4:81-83.
101. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1 in autoinflammatory diseases. Arthritis Rheum. 2011;63:314-324.
102. Savic S, Dickie LJ, Wittmann M, McDermott MF. Autoinflammatory syndromes and cellular responses to stress: Pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol. 2012;26: 505-533.
103. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117: 3720-3732.
104. Caorsi R, Federici S, Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev. 2012;12: 81-86.
105. Blech M, Peter D, Fischer P, et al. One target-Two different binding modes: Structural insights into gevokizumab and canakinumab interactions to interleukin-1b. J Mol Biol. 2013;1:94-111.
106. Yosipovitch G, Sholat B, Bshara J, et al. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: Correlations with disease activity and severity. Isr J Med Sci. 1995;31:345-348.
107. Düzgün N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: Soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease. Rheumatol Int. 2005;25:1-5.
108. Özcimen AA, Dilek K, Bingöl Ü, et al. IL-1 cluster gene polymorphisms in Turkish patients with Behçet's disease. Int J Immunogenet. 2011;38:295-301.
109. Botsios C, Sfriso P, Furlan A, Punzi L. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149: 284-286.
110. Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis. 2012;71:1589-1591.
111. Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):115.
112. Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1bregulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: An open label study. Ann Rheum Dis. 2012;71:563-566.
113. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005;52:1960-1967.
114. Lockwood CM, Hale G, Waldman H, Jayne DRW. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology. 2003;42:1539-1544.
115. Buggage RR, Levy-Clarke G, Sen HN, et al. A doublemasked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm. 2007;15: 63-70.
116. Sadreddini S, Noshad H, Molaeefard M, Hoshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol. 2008;18:306-308.
117. Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet's disease: Randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246-252.
118. Hirano T, Ohguro N, Hohki S, et al. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22: 298-302.
119. Dick A, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-787.
120. Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol. 2011;128:655-664.
121. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010;42:698-702.
122. Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet. 2010;42: 703-706.
123. Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B. 51 and ERAP1. Nat Genet. 2013;45:202-207.
124. Kitaichi N, Miyazaki A, Stanford MR, et al. Low prevalence of juvenile-onset Behçet's disease with uveitis in East/South Asian people. Br J Ophthalmol. 2009;93: 1428-1430.
125. Kone-Paut I, Darce-Bello M, Shahram F, et al. Registries in rheumatological and musculoskeletal conditions: Paediatric Behçet's disease-An international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011;50:184-188.
126. Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behçet disease: A descriptive study of 36 cases. Am J Ophthalmol. 2003;136:1114-1119.
127. Citirik M, Berker N, Songur MS, et al. Ocular findings in childhood-onset Behçet disease. J AAPOS. 2009;13: 391-395.
128. Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric Behçet disease in the American Midwest. Am J Ophthalmol. 2008;146:819-827.
129. Kramer M, Amer R, Mukamer M, et al. Uveitis in juvenile Behçet's disease:clinical course and visual outcome compared with adult patients. Eye. 2009;23:2034-2041.
130. Sungur GK, Hazirolan D, Yalvac I, et al. Clinical and demographic evaluation of Behçet disease among different paediatric age groups. Br J Ophthalmol. 2009;93: 83-87.
131. Borlu M, Uksal Ü, Ferahbas A, Evereklioglu C. Clinical features of Behçet's disease in children. Int J Dermatol. 2006;45:713-716.
132. Atmaca L, Boyvat A, Yalçindag FN, et al. Behçet disease in children. Ocul Immunol Inflamm. 2011;19:103-107.
133. Guillame-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-Alpha in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology (Oxford). 2007;46:1570-1573.
134. Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-Alpha-A new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. Rheumatology (Oxford). 2008;47:1051-1053.
135. Yoshida A, Kaburaki T, Okinaga K, et al. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012;56:536-543.
136. Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-Term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol. 2005;26:83-92.
137. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45: 982-989.
138. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341-1344.
139. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS. 2008;12:611-613.
140. Atmaca LS, Yalçindaǧ FN, Ozdemir O. Intravitreal triamcinolone acetonide inthe management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:451-456.
141. Park UC, Park JH, Yu HG. Long-Term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease. Ocul Immunol Inflamm. 2013. [Epub ahead of print].
142. Lowder C, Belfort Jr. R, Lightman S, et al. Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545-553.
143. Mirshahi A, Namavari A, Djalilian A, et al. Bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease. Ocul Immunol Inflamm. 2009;17:59-64.
144. Erdurman FC, Durukan AH, Mumcuoǧlu T, Hürmeriç V. Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis. Ocul Immunol Inflamm. 2009; 17:56-58.
145. Atmaca LS, Batioǧlu F, Idil A. Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1996;234: 94-99.
146. Hu K, Lei B, Kijlstra A, et al. Male sex, erythema nodosum, and electroretinography as predictors of visual prognosis after cataract surgery in patients with Behçet disease. J Cataract Refract Surg. 2012;38:1382-1388.
147. Berker N, Soykan E, Elgin U, Ozkan SS. Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behçet's disease. Ophthalmic Surg Lasers Imag. 2004;35:215-218.
148. Krause L, Altenburg A, Bechrakis NE, et al. Intraocular surgery under systemic interferon-Alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:1617-1621.
149. Nishida T, Shibuya E, Asukata Y, et al. Clinical course before and after cataract and glaucoma surgery under systemic infliximab therapy in patients with Behçet's disease. Case Rep Ophthalmol. 2011;2:189-192.
150. Handa T, Tsunekawa H, Zako M. Cataract surgery in Behçet's disease patients one week after infliximab administration. Case Rep Ophthalmol. 2011;2:176-178.
151. Mesquida M, Pelegrín L, Llorenç V, et al. Pars plana vitrectomy for vitreoretinal complications of Behçet uveitis. Eur J Ophthalmol. 2012 Sep 26:0. doi: 10.5301/ ejo.5000194. [Epub ahead of print].
152. Sullu Y, Alotaiby H, Beden U, Erkan D. Pars plana vitrectomy for ocular complications of Behçet's disease. Ophthalmic Surg Lasers Imag. 2005;36:292-297.